Showing results (51-60 of 64) with videos related to
Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|June 23, 2025
Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancerWiem Lassoued, Ravi A Madan, Elisabetta Xue, et al.Nature Communications|February 15, 2020
A case report of multiple primary prostate tumors with differential drug sensitivityScott Wilkinson, Stephanie A Harmon, Nicholas T Terrigino, et al.Journal for Immunotherapy of Cancer|December 16, 2020
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignanciesJulius Strauss, Margaret E Gatti-Mays, Byoung Chul Cho, et al.Nature Cancer|July 14, 2021
Accelerating precision medicine in metastatic prostate cancerJoaquin Mateo, Rana McKay, Wassim Abida, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.Journal for Immunotherapy of Cancer|December 6, 2018
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, David VanderWeele, Ravi A Madan, et al.Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.Med (New York, N.Y.)|December 13, 2022
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptomeGal Dinstag, Eldad D Shulman, Efrat Elis, et al.Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.European Urology|March 31, 2021
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal TherapyScott Wilkinson, Huihui Ye, Fatima Karzai, et al.Pageof 7